Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (Nasdaq: CTMX) announced significant findings related to its investigational drug pacmilimab (CX-072) in three peer-reviewed publications. Pacmilimab exhibited single-agent activity in advanced solid tumors, notably in metastatic triple-negative breast cancer (TNBC). It demonstrated potential for combination therapies with ipilimumab, addressing limitations of conventional immune checkpoint inhibitors. The overall objective response rate (ORR) in patients treated was 12%, with a disease control rate of 42%. Results suggest pacmilimab may provide a safer alternative with reduced toxicity.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in two upcoming virtual investor conferences. The BTIG 5th Virtual Biotechnology Conference is scheduled for August 9, 2021, at 1:00 p.m. ET, followed by the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, with a panel discussion at 1:10 p.m. ET. CytomX focuses on developing Probody therapeutics, which are designed to selectively target tumors and minimize toxicity. The company collaborates with leaders in the biotechnology sector and has a robust clinical pipeline.
CytomX Therapeutics (Nasdaq: CTMX) announced the upcoming release of its second quarter 2021 financial results on August 5, 2021, after U.S. market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide updates on corporate developments. CytomX focuses on developing conditionally activated therapeutics utilizing its Probody® technology platform, aimed at enhancing cancer treatment efficacy while minimizing toxicity. The company collaborates with prominent firms like AbbVie and Bristol Myers Squibb on various clinical-stage assets.
CytomX Therapeutics reported positive results from the Phase 1 study of CX-2029, the first CD71-targeting antibody-drug conjugate (ADC), highlighting its well-tolerated safety profile.
The study, published in Clinical Cancer Research, involved 45 patients with advanced solid tumors, showing encouraging anti-tumor responses at doses of 2 mg/kg and higher.
The recommended Phase 2 dose is 3 mg/kg every three weeks. The ongoing Phase 2 expansion study targets various cancers, with initial results expected in Q4 2021.
CytomX Therapeutics (Nasdaq: CTMX) is set to participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:00 p.m. ET. Dr. Amy Peterson, chief development officer, will represent the company during this event. Investors can access a live webcast on CytomX’s website with an archived replay available for 30 days post-event. CytomX is a leader in oncology-focused therapeutics, utilizing its Probody technology to develop safer, more effective cancer treatments through conditionally activated biologics.
CytomX Therapeutics, Inc. (CTMX) reported its Q1 2021 financial results, highlighting a revenue decrease to $16 million from $49.6 million Y/Y, primarily due to reduced milestone payments. Cash reserves rose to $393.8 million, bolstered by a $108 million public offering. Key advancements include ongoing Phase 2 studies for praluzatamab ravtansine (CX-2009) and CX-2029, targeting unmet cancer needs. The company also faced delays in IND submissions for CX-2043 due to supply chain issues, while expanding collaborations with Bristol Myers Squibb and Amgen.
CytomX Therapeutics (Nasdaq: CTMX) announced it will report its first quarter 2021 financial results on May 6, 2021, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results and provide a corporate update. CytomX focuses on developing conditionally activated antibody therapeutics for cancer treatment, leveraging its Probody technology. Currently, CytomX has five clinical-stage assets, four in Phase 2 studies, including promising candidates targeting cancer-specific antigens.
CytomX Therapeutics, a clinical-stage biopharmaceutical company, announced the granting of stock options to two new employees. As of April 1, 2021, one employee received options for 120,000 shares at $7.87, and another on April 12, 2021, for 275,000 shares at $6.74. These grants were made under the 2019 Employment Inducement Incentive Plan to attract talent. CytomX focuses on conditionally activated antibody therapeutics targeting cancer, with partnerships with prominent companies such as AbbVie and Bristol Myers Squibb.
CytomX Therapeutics, a clinical-stage oncology biopharmaceutical company, announced a virtual investor event scheduled for April 7, 2021, from 1:00 p.m. to 3:00 p.m. ET. The event will feature industry experts including John Lambert, Sara M. Tolaney, and Melissa L. Johnson, focusing on CytomX’s Probody technology and two investigational ADCs, praluzatamab ravtansine (CX-2009) and CX-2029. A live webcast will be available on CytomX's website, with a replay accessible for 30 days post-event. The company aims to develop safer, more effective cancer therapies.
CytomX Therapeutics (CTMX) reported strong advancements in its clinical pipeline, highlighted by a three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) for breast cancer. The company also continues to enroll patients in the CX-2029 Phase 2 expansion study across four cancer types in collaboration with AbbVie, and Bristol Myers Squibb has expanded its Probody Program into three additional cancer types. In 2020, total revenues reached $100.4 million, up from $57.5 million in 2019, with cash reserves at $316.1 million. The company aims to report initial Phase 2 data in Q4 2021.